• Menu
• » Administrative Rules Related
• » Statements of Scope
• » All Scope Statements

Controlled Substances Board (CSB) Stop grouping [View All]

• SS 088-24

  CR 24-085

  2/5/2027

  Relating to: Scheduling 2-methyl AP–237
• SS 087-24

  CR 24-084

  2/5/2027

  Relating to: Scheduling ADB-BUTINACA, a-PiHP, and 3-MMC
• SS 086-24

  CR 24-083

  2/5/2027

  Relating to: Scheduling 5 synthetic cannabinoids
• SS 049-24

  CR 24-059

  11/13/2026

  Relating to: Scheduling nine fentanyl-related substances
• SS 048-24

  CR 24-058

  11/13/2026

  Relating to: Scheduling zuranolone
• SS 022-24

  CR 24-060

  8/12/2026

  Relating to: Mail delivered prescriptions
• SS 001-24

  CR 24-048

  7/2/2026

  Relating to: Transferring flualprazolam and scheduling 4 other synthetic benzodiazepine substances
• SS 079-23

  CR 24-024

  4/23/2026

  Relating to: Excluding fenfluramine
• SS 078-23

  CR 24-023

  4/23/2026

  Relating to: Scheduling methiopropamine
• SS 055-23

  CR 24-033

  2/7/2026

  Relating to: Monitored prescription drug history reports
• SS 054-23

  CR 24-005

  2/7/2026

  Relating to: Scheduling Mesocarb
• SS 053-23

  CR 24-004

  2/7/2026

  Relating to: Excluding [18F]FP-CIT
• SS 052-23

  CR 23-069

  2/7/2026

  Relating to: Scheduling Zipeprol
• SS 051-23

  CR 23-068

  2/7/2026

  Relating to: Scheduling Amineptine
• SS 095-22

  CR 24-013

  5/21/2025

  Relating to: National provider identifier requirement
• SS 094-22

  CR 23-021

  5/21/2025

  Relating to: Scheduling Ganaxolone
• SS 093-22

  CR 23-020

  5/21/2025

  Relating to: Scheduling seven (7) synthetic benzimidazole-opioid substances
• SS 092-22

  CR 23-019

  5/21/2025

  Relating to: Scheduling Daridorexant
• SS 091-22

  CR 23-018

  5/21/2025

  Relating to: Scheduling thirty-eight (38) anabolic steroids
• SS 015-22

  CR 22-054

  8/28/2024

  Relating to: Scheduling 4,4’-Dimethylaminorex
• SS 096-21

  CR 22-040

  4/18/2024

  Relating to: Transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP
• SS 095-21

  CR 22-038

  4/18/2024

  Relating to: Scheduling perampanel
• SS 094-21

  CR 22-039

  4/18/2024

  Relating to: Scheduling lacosamide
• SS 093-21

  CR 22-037

  4/18/2024

  Relating to: Scheduling embutramide
• SS 092-21

  CR 22-036

  4/18/2024

  Relating to: Scheduling fospropofol
• SS 091-21

  CR 22-035

  4/18/2024

  Relating to: Excluding 6-beta-naltrexol
• SS 090-21

  CR 22-034

  4/18/2024

  Relating to: Scheduling alfaxalone
• SS 089-21

  CR 22-033

  4/18/2024

  Relating to: Scheduling ten (10) fentanyl related substances
• SS 088-21

  CR 22-032

  4/18/2024

  Relating to: Scheduling serdexmethylphenidate
• SS 072-21

  CR 22-016

  2/29/2024

  Relating to: Scheduling brorphine
• SS 071-21

  CR 22-014

  2/29/2024

  Relating to: Scheduling remimazolam
• SS 070-21

  CR 22-011

  2/29/2024

  Relating to: Scheduling crotonyl fentanyl
• SS 061-21

  CR 21-098

  12/28/2023

  Relating to: Scheduling oliceridine
• SS 126-20

  EmR2037
  CR 20-079

  3/28/2023

  Relating to: Scheduling flualprazolam
• SS 123-20

  CR 20-075

  2/24/2023

  Relating to: Scheduling of Cenobamate
• SS 122-20

  CR 20-076

  2/24/2023

  Relating to: Scheduling of lemborexant
• SS 121-20

  CR 20-077

  2/24/2023

  Relating to: Removing FDA approved cannabidiol from schedule V and excluding from Schedule I
• SS 120-20

  CR 20-078

  2/24/2023

  Relating to: Scheduling of Norfentanyl
• SS 076-20

  CR 20-058

  12/15/2022

  Relating to: Scheduling of Lasmiditan
• SS 047-20

  EmR2017
  CR 20-022

  11/26/2022

  Relating to: Scheduling MMB-FUBICA and 4F-MDMB-BINACA
• SS 034-20

  EmR2013
  CR 20-023

  11/11/2022

  Relating to: Scheduling Isotonitazene and 1P-LSD
• SS 012-20

  CR 20-049

  9/23/2022

  Relating to: Scheduling of brexanolone and solriamfetol
• SS 011-20

  CR 20-050

  9/23/2022

  Relating to: Relating to: Scheduling of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP
• SS 010-20

  CR 20-051

  9/23/2022

  Relating to: Scheduling of noroxymorphone
• SS 111-19

  CR 20-080

  5/4/2022

  Relating to: Designating Gabapentin as a monitored drug
• SS 108-19

  CR 20-048

  5/4/2022

  Relating to: Scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144
• SS 124-18

  CR 19-157

  6/11/2021

  Relating to: Special use authorizations
• SS 121-18

  CR 19-012

  6/3/2021

  Relating to: Scheduling of FDA approved cannabidiol drugs
• SS 120-18

  CR 19-011

  6/3/2021

  Relating to: Scheduling of N-Ethylpentylone
• SS 118-18

  CR 19-156

  5/19/2021

  Relating to: Operation of PDMP
• SS 117-18

  CR 19-010

  5/19/2021

  Relating to: Scheduling of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA
• SS 059-18

  CR 18-070

  11/29/2020

  Relating to: Scheduling of Para-chloroisobutyryl fentanyl
• SS 058-18

  CR 18-069

  11/29/2020

  Relating to: Scheduling of MT-45
• SS 030-18

  9/26/2020

  Relating to: Approval of pharmacies and physicians that may dispense cannabidiol
• SS 023-18

  CR 18-055

  9/5/2020

  Relating to: Scheduling of oral solutions containing dronabinol
• SS 015-18

  CR 18-022

  8/19/2020

  Relating to: Scheduling of FUB-AMB
• SS 014-18

  CR 18-023

  8/19/2020

  Relating to: Scheduling of ortho-fluorofentanyl
• SS 013-18

  CR 18-024

  8/19/2020

  Relating to: Exclusion of naldemedine from scheduling
• SS 075-17

  CR 17-075

  2/14/2020

  Relating to: Scheduling cyclopropyl fentanyl
• SS 074-17

  CR 17-089

  2/14/2020

  Relating to: Scheduling of 4-Fluoroisobutyryl Fentanyl
• SS 073-17

  CR 17-088

  2/14/2020

  Relating to: Scheduling of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA
• SS 064-17

  CR 17-085

  2/4/2020

  Relating to: Scheduling AB-CHMINACA, AB-PINACA and THJ-2201
• SS 063-17

  CR 17-087

  2/4/2020

  Relating to: Scheduling of 4-MePPP and a-PBP
• SS 062-17

  CR 17-086

  2/4/2020

  Relating to: Scheduling MAB-CHMINACA
• SS 036-17

  EmR1710
  CR 17-040

  2/4/2020

  Relating to: Scheduling acryl fentanyl
• SS 015-17

  CR 17-020

  2/4/2020

  Relating to: Scheduling of U-47700
• SS 010-17

  CR 17-022

  2/4/2020

  Relating to: Scheduling of Eluxadoline
• SS 009-17

  CR 17-023

  2/4/2020

  Relating to: Scheduling of AH-7921
• SS 008-17

  CR 17-021

  2/4/2020

  Relating to: Scheduling of acetyl fentanyl
• SS 004-17

  CR 17-008

  2/4/2020

  Relating to: Scheduling of AB-FUBINACA and ADB-PINACA
• SS 003-17

  CR 17-007

  2/4/2020

  Relating to: Scheduling of thiafentanil
• SS 002-17

  CR 17-009

  2/4/2020

  Relating to: Scheduling of brivaracetam
• SS 095-16

  CR 16-081

  2/4/2020

  Relating to: Scheduling beta-hydroxythiofentanyl and butytyl fentanyl
• SS 071-16

  CR 16-060

  2/4/2020

  Relating to: Removing [123I]ioflupane as a controlled substance
• SS 070-16

  EmR1626
  CR 16-059

  2/4/2020

  Relating to: Scheduling furanyl fentanyl
• SS 031-16

  EmR1706
  CR 17-028

  2/4/2020

  Relating to: Prescription drug monitoring program
• SS 103-15

  CR 15-101

  2/4/2020

  Relating to: Operation of PDMP
• SS 102-15

  CR 15-083

  2/4/2020

  Relating to: Controlled substance measurements for special use authorizations
• SS 037-15

  CR 15-068

  2/4/2020

  Relating to: Removing naloxegol as a controlled substance
• SS 120-14

  CR 15-007

  2/4/2020

  Relating to: Rescheduling hydrocodone combination products as schedule II controlled substances
• SS 119-14

  CR 15-008

  2/4/2020

  Relating to: Scheduling tramadol as a schedule IV controlled substance
• SS 118-14

  CR 15-009

  2/4/2020

  Relating to: Scheduling suvorexant as a schedule IV controlled substance
• SS 077-13

  CR 14-009

  2/4/2020

  Relating to: Denial of special use authorization permit
• SS 076-13

  CR 14-009

  2/4/2020

  Relating to: Granting a limited special use authorization permit
• SS 062-13

  EmR1318

  2/4/2020

  Relating to: Additions to schedules in Chapter 961, Wis. Stats.
• SS 061-13

  2/4/2020

  Relating to: Additions to schedules in Chapter 961, Wis. Stats.